Multi-agent Low Dose Chemotherapy GAX-CI Followed By Olaparib And Pembro In Metastatic Pancreatic Ductal Cancer.

Study Overview

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

The purpose of this study is to evaluate the safety and clinical activity of maintenance olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated metastatic pancreatic ductal cancer.

N/A

Metastatic Pancreatic Cancer

DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Irinotecan
DRUG: Capecitabine
DRUG: Pembrolizumab
DRUG: Olaparib

J2112
IRB00267980 (OTHER Identifier) (OTHER: Johns Hopkins Medicine Institutional Review Board)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2021-02-09	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-06-10
First Submitted that Met QC Criteria 2021-02-09	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-06-11
First Posted (ACTUAL) 2021-02-15	Results First Posted N/A	Last Verified 2025-06

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine Maintenance of Pembrolizumab and Olaparib	DRUG: Nab-paclitaxel 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: Abraxane DRUG: Gemcitabine 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: Gemzar DRUG: Cisplatin 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: N/A DRUG: Irinotecan 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: N/A DRUG: Capecitabine 1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days). 2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days). 3. Other Name: Xeloda DRUG: Pembrolizumab 1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase. 2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks). 3. Other Name: MK-3475; Keytruda DRUG: Olaparib 1. Patients will receive treatment on Days 1-21 during the maintenance phase. 2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days). 3. Other Name: Lynparza

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine

Maintenance of Pembrolizumab and Olaparib

DRUG: Nab-paclitaxel

1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: Abraxane

DRUG: Gemcitabine

1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: Gemzar

DRUG: Cisplatin

1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: N/A

DRUG: Irinotecan

1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days). 2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle). 3. Other Name: N/A

DRUG: Capecitabine

1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days). 2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days). 3. Other Name: Xeloda

DRUG: Pembrolizumab

1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase. 2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks). 3. Other Name: MK-3475; Keytruda

DRUG: Olaparib

1. Patients will receive treatment on Days 1-21 during the maintenance phase. 2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days). 3. Other Name: Lynparza

Primary Outcome Measures	Measure Description	Time Frame
Progression-free Survival (PFS) after 6 months according to RECIST 1.1 criteria.	PFS is defined as the 6 month from the date of randomization to disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.	6 Months
Progression-free Survival (PFS) after 6 months according to IRECIST criteria.	PFS is defined as the 6 month from the date of randomization to disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using iRECIST criteria) or death due to any cause. Per iRECIST criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.	6 months

Secondary Outcome Measures	Measure Description	Time Frame
Number of participants experiencing grade 3 or above drug-related toxicities	• When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject. Estimation based on the Kaplan-Meier curve.	4 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Colleen Apostal, RN

Phone Number: 410-614-3644

Email: GIClinicaltrials@jhmi.edu

Study Contact Backup

Name: Joann Santmyer, RN

Phone Number: 410-614-3644

Email: jsantmy1@jhmi.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Cohort 1 - Subject has stable disease as measured by RECIST 1.1 or iRECIST after 6 cycles of GAX-CI.
Cohort 2 - Subject has progressive disease as measured by RECIST 1.1 and iRECIST prior to 6 cycles of GAX-CI.
Ability to understand and willingness to sign a written informed consent document.
Age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Have metastatic histologically or cytologically-proven ductal pancreatic cancer.
Patients must not have received prior treatment for pancreatic cancer.
Have measurable disease based on RECIST 1.1.
Willing to have to a tumor biopsy.
Patients must have adequate organ and marrow function defined by study - specified laboratory tests.
Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
Men must use acceptable form of birth control while on study.
Participant understands the study regimen, its requirements, risks and discomforts, competent to report AE, understand the drug dosing schedule and use of medications to control AE.

Patients who will be considered for surgery are ineligible.
Had chemotherapy within 5 years prior to study treatment.
Have received any investigational drugs within 28 days prior to study treatment.
Had surgery within 28 days of dosing of investigational agent.
Has history of central nervous system (CNS) metastases and/or carcinomatous meningitis.
Require any antineoplastic therapy.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent.
Has received prior therapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan, or PARP inhibitor.
Hypersensitivity reaction to any monoclonal antibody.
Is taking a moderate or strong CYP3A inhibitor.
Has uncontrolled acute or chronic medical illness.
Has known additional malignancy that is progressing and requires active treatment.
Has received radiotherapy for pancreatic cancer.
Have received any live vaccine or live-attenuated, any allergen hyposensitization therapy, growth factors or major surgery within 30 days prior to study treatment.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
Has active autoimmune disease.
Has an active known or suspected autoimmune disease or is receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug.
Prior tissue or organ allograft or allogeneic bone marrow transplantation.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Requirement for daily supplemental oxygen.
Patients with a history of (non-infectious) pneumonitis/interstitial lung disease that requires steroids.
Subject with clinically significant wound.
Has a confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.
Infection with HIV.
Has active Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C virus (defined as hepatitis C virus (HCV) RNA [qualitative] is detected) infection. Patients who are Hepatitis C antibody positive and viral load negative will be permitted to enroll.
Has uncontrolled infection.
Unwilling to have blood drawn.
Has known psychiatric or substance use disorder that would interfere with cooperation with the requirements of the trial.
Woman who are pregnant or breastfeeding.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Merck Sharp & Dohme LLC

Investigators

PRINCIPAL_INVESTIGATOR: Dung Le, MD, SKCCC Johns Hopkins Medical Institution

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record